

1. COVID-19 vaccines approved for Manufacture for Sale or for Distribution in the country

No	Vaccine	Applicant	Date of EUA	Date of approval	Age group	Dosing schedule	Route & Storage	Shelf Life as on 04.10.2022
1	ChAdOx1 nCoV-19 Corona Virus Vaccine Recombinant (COVISHIELD)	M/s Serum Institute of India Pvt. Ltd.	03.01.2021	27.01.2022	≥ 18 years	Two doses, 4 to 6 weeks apart (Overseas Data available for 12weeks)	Intramuscular, 2- 8°C	9 months
2	Whole Virion Inactivated SARS-CoV- 2 Vaccine (COVAXIN)	M/s Bharat Biotech International Limited	03.01.2021	27.01.2022	≥ 18 years	Two doses, Day 0 & 28	Intramuscular, 2- 8°C	12 months
3	SARS-CoV-2 vaccine containing Receptor Binding Domain (RBD) of SARS-CoV-2 gene (CORBEVAX)	M/s Biological E Limited	28.12.2021	01.07.2025	≥ 12 years	Two doses, Day 0 & 28	Intramuscular, 2- 8°C	12 months
4	COVID-19 Vaccine, Adjuvanted (SARS-CoV-2 rS Protein (COVID-19) Nanoparticle Vaccine, (Omicron JN.1 Variant) with Matrix M1 adjuvant (also denoted as Matrix-M) (COVOVAX)	M/s Serum Institute of India Pvt. Ltd.	28.12.2021	07.04.2026	≥ 12 years	Single dose	Intramuscular, 2- 8°C	12 months

Note: COVISHIELD, COVAXIN, CORBEVAX & COVOVAX vaccines were initially approved for Restricted Use in Emergency Situation in the country on 03.01.2021, 03.01.2021 and 28.12.2021 respectively.

2. COVID-19 vaccines approved for Primary vaccination series for Restricted Use in Emergency Situation in the country

Sr.No	Vaccine	Applicant	Date of approval	Age group	Dosing schedule	Route & Storage	Shelf Life as on 04.10.2022
1	Gam COVID Vac (component I & II) (SPUTNIK-V)	M/s Dr. Reddy's Lab. Ltd. (Importer)	12.04.2021	≥ 18 years	Two doses, Day 0 (comp I) & Day 21 (comp II)	Intramuscular, -18°C	12 months
2	mRNA-1273COVID-19 vaccine (Moderna vaccine)	M/s Cipla Ltd. (Importer)	29.06.2021	≥ 18 years	Two doses, Day 0 & 28	Intramuscular, -25°C to -15°C	7 months
3	Gam COVID Vac (component I & II) (SPUTNIK-V)	M/s Panacea Biotec Ltd	02.07.2021	≥ 18 years	Two doses, Day 0 (comp I) & Day 21 (comp II)	Intramuscular, -18°C	12 months
4	COVID-19 vaccine (Ad26.COV2-S) [recombinant] (Janssen Vaccine)	M/s Johnson & Johnson Pvt. Ltd. (Importer)	07.08.2021	≥ 18 years	Single dose	Intramuscular, -25°C to -15°C & 2-8°C	6 months
5	COVID-19 vaccine (Ad26.COV2-S) [recombinant] (Janssen Vaccine)	M/s Biological E Limited	18.08.2021	≥ 18 years	Single dose	Intramuscular, -25°C to -15°C & 2-8°C	6 months
6	Novel Corona Virus-2019-nCov vaccine (rDNA) (ZyCoV-D)	M/s Cadila Healthcare Limited	20.08.2021	≥ 12 years	Three doses Day 0, 28 & 56	Intradermal, 2°-8°C	12 months
7	Gam COVID Vac (component I & II) (SPUTNIK-V)	M/s Hetero Biopharma Ltd	07.10.2021	≥ 18 years	Two doses, Day 0 (comp I) & Day 21 (comp II)	Intramuscular, -18°C	6 months

Sr. No	Vaccine	Applicant	Date of approval	Age group	Dosing schedule	Route & Storage	Shelf Life as on 04.10.2022
8	Whole-Virion Inactivated SARS-CoV-2 Vaccine (COVAXIN)	M/s Bharat Biotech International Limited	24.12.2021	≥ 12 to 18 years	Two doses, Day 0 & 28	Intramuscular, 2- 8°C	12 months
			26.04.2022	>6 to <12 years			
9	SARS-CoV-2 vaccine containing Receptor Binding Domain (RBD) of SARS-CoV-2 gene (CORBEVAX)	M/s Biological E Limited	26.04.2022	≥5 to < 12 years	Two doses, Day 0 & 28	Intramuscular, 2- 8°C	18 months
10	SARS-CoV-2 rS Protein (COVID-19) recombinant spike protein Nanoparticle Vaccine (COVOVAX)	M/s Serum Institute of India Pvt. Ltd.	28.12.2021	≥ 18 years	Two doses, Day 0 & 21	Intramuscular, 2- 8°C	9 months
			08.03.2022	≥ 12 years			
			28.06.2022	≥ 7 to < 12 years			
11	Recombinant adenoviral vector vaccine containing particles of serotype 26 containing the protein S gene of the SARS-CoV-2 virus (SPUTNIK Light)	M/s Dr. Reddy's Lab. Ltd. (Importer)	05.02.2022	≥ 18 years	Single dose	Intramuscular, -18°C	6 months
12	Recombinant adenoviral vector vaccine containing particles of serotype 26 containing the protein S gene of the SARS-CoV-2 virus (SPUTNIK Light)	M/s Hetero Biopharma Ltd	16.03.2022	≥ 18 years	Single dose	Intramuscular, -18°C	6 months
13	Novel Corona Virus-2019-nCov vaccine (rDNA) (ZyCoV-D)	M/s Cadila Healthcare Limited	26.04.2022	≥ 12 years	Two doses, Day 0 & 28	Intradermal, 2-8°C	9 months
14	Lyophilized mRNA Vaccine for Injection (COVID-19) (HGCO-19)	M/s Gennova Biopharmaceuticals Limited	28.06.2022	≥ 18 years	Two doses, Day 0 & 28	Intramuscular, 2- 8°C	6 months
15	ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant COVID-19 Vaccine (iNCOVACC)	M/s Bharat Biotech International Limited	06.09.2022	≥ 18 years	Two doses, Day 0 & 28	Intra Nasal 2-8°C	6 Months

3. COVID-19 vaccines approved for Booster (third) dose vaccination for Restricted Use in Emergency Situation in the country.

Sr. No	Vaccine	Applicant	Date of approval	Age group	Dosing schedule	Route & Storage
1	SARS-CoV-2 vaccine containing Receptor Binding Domain (RBD) of SARS-CoV-2 gene (CORBEVAX)	M/s Biological E Limited	03.06.2022	≥18 years	Single dose to be administered 6 months after primary vaccination (two doses) with COVAXIN or COVISHIELD.	Intramuscular, 2- 8°C
2	SARS-CoV-2 rS Protein (COVID-19) recombinant spike protein Nanoparticle Vaccine (COVOVAX)	M/s Serum Institute of India Pvt. Ltd.	16.01.2023	≥ 18 years	Single dose to be administered 6 months after primary vaccination (two doses) with COVAXIN or COVISHIELD.	Intramuscular, 2-8°C
3	Novel Corona Virus 2019-nCoV Vaccine (Recombinant) (3 mg, Single dose) (ZyCoV-D)	M/s Zydus Lifesciences Limited	20.04.2023	≥ 18 years	Single dose booster (third) dose of Novel Corona Virus 2019-nCoV Vaccine (Recombinant) (3mg, Single dose) to individuals aged ≥18 years after 6 months of primary vaccination (of 2 doses) of either COVAXIN or COVISHIELD.	Intradermal, 2-8°C
4	ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant COVID- 19 Vaccine (iNCOVACC)	M/s Bharat Biotech International Limited	24.11.2022	≥ 18 years	To administer booster dose (third dose) after 6 months to individuals of age >18 years who have already administered primary (two doses) of COVAXIN or COVISHIELD vaccines	Intra Nasal, 2-8°C
5	Lyophilized mRNA Vaccine for Injection (COVID-19) (GEMCOVAC-OM)	M/s Gennova Biopharmaceuticals Ltd.	07.07.2023	≥ 18 years	Single booster dose in individuals aged ≥18 years administered at least 4 months after completion of primary vaccination with either COVISHIELD or COVAXIN.	Intradermal, 2-8°C